STING WT Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Stimulator of interferon genes (STING, or TMEM173) is an endoplasmic reticulum-associated protein that functions as a major regulator of the innate immune response to viral, bacterial infections, highly expressed in hematopoietic cells including T lymphocytes, NK cells, monocytes, myeloid cells as well as various endothelial or epithelial cells and lung, heart, smooth muscle. STING signal pathway is activated by cyclic dinucleotides (CDNs) secreted by intracellular bacteria or 2’3’-cGAMP derived from the intracellular enzyme, cyclic GMP-AMP synthase (cGAS), upon invasion by pathogens and exposure to aberrant self-DNA, which leads to the production of interferons and proinflammatory cytokines. Targeting STING may be a potential for treatment of cancer and modulation of immune responses.
Family:
Immune System
Class:
PRR
Protein Name:
STING_HUMAN
Uniprot Number:
Q86WV6
Gene Name:
STING
Gene ID:
340061
Gene Aliases:
STING, TMEM173
Accession Number:
MF622062.1
Organism:
Human
Construct Details:
Full Length, Recombinant
Cell Type:
HEK293T/17
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Agonist
Detection Method:
Luminescence
Platform:
Plate reader
Measured Response:
Luminescence
Testing Information
Procedure Summary:
HEK293T/17 cells are seeded overnight with reporter and human STING WT transfected mixture. Test compound and/or vehicle is incubated with cells at 37°C, 5% CO₂ for 6 hours. The STING response is evaluated by luciferase assay. Luminescence is measured using a microplate reader. Induction of STING response by 50 percent or more (≥50%) relative to 1 μM diABZI indicates significant response activity. Inhibition of STING response by 50 percent or more (≥50%) relative to 10 nM diABZI indicates significant STING antagonist activity.
Incubation:
360 min at 37°C
Control Activator:
diABZI
Criteria For Significance:
≥ 50% response of diABZI-induced luminescence
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
20 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Adverse / Beneficial Action:
Potential benefit in the treatment of cancer and modulation of immune responses
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS
STING Human Variant LeadHunter Panel - TW
Item: PP316
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
